Institution
University of Bedfordshire
Education•Luton, Bedford, United Kingdom•
About: University of Bedfordshire is a education organization based out in Luton, Bedford, United Kingdom. It is known for research contribution in the topics: Population & Context (language use). The organization has 3860 authors who have published 6079 publications receiving 143448 citations. The organization is also known as: University of Luton.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The potential for the development of bacteriophage therapy in the context of critical aspects of modern, regulated clinical trials is discussed.
Abstract: Antibiotic resistance is now recognized as a major, global threat to human health and the need for the development of novel antibacterial therapies has become urgent. Lytic bacteriophages (phages) targeting individual bacterial pathogens have therapeutic potential as an alternative or adjunct to antibiotic use. Bacteriophage therapy has been used for decades, but clinical trials in this field are rare, leaving many questions unanswered as to its effectiveness for many infectious diseases. As a consequence bacteriophage therapy is not used or accepted in most parts of the world. The increasing need for new antimicrobial therapies is driving the development of bacteriophage therapies for a number of diseases but these require the successful completion of large-scale clinical trials in accordance with US FDA or European EMA guidelines. Bacteriophages are considered as biological agents by regulatory authorities and they are managed by biological medicinal products guidelines for European trials and guidelines of the division of vaccines and related product applications in the USA. Bacteriophage therapy is typically an 'active' treatment requiring multiplication in the bacterial host and therefore the factors that govern its success are different from those of conventional antibiotics. From the pharmacokinetic and pharmacodynamic points of view, time of treatment, dosage depending on the site of infection and the composition of the bacteriophage formulation (single vs multiple strains) need careful consideration when designing clinical trials. Scientific evidence regarding inflammatory effects, potential for gene transfer and phage resistance, need to be evaluated through such trials. However purity, stability and sterility of preparations for human use can be addressed through Good Manufacturing Practises to reduce many potential safety concerns. In this review we discuss the potential for the development of bacteriophage therapy in the context of critical aspects of modern, regulated clinical trials.
99 citations
••
TL;DR: Results obtained in rodent cell lines with impaired p53 function and human p53-competent cells suggest that a reduction in the percentage of non-relevant positive results for carcinogenicity prediction can be achieved by careful selection of cells used without decreasing the sensitivity of the assays.
Abstract: Improving current in vitro genotoxicity tests is an ongoing task for genetic toxicologists. Further, the question on how to deal with positive in vitro results that are demonstrated to not predict genotoxicity or carcinogenicity potential in rodents or humans is a challenge. These two aspects were addressed at the 5th International Workshop on Genotoxicity Testing (IWGT) held in Basel, Switzerland, on August 17-19, 2009. The objectives of the working group (WG) were to make recommendations on the use of cell types or lines, if possible, and to provide evaluations of promising new approaches. Results obtained in rodent cell lines with impaired p53 function (L5178Y, V79, CHL and CHO cells) and human p53-competent cells (peripheral blood lymphocytes, TK6 and HepG2 cells) suggest that a reduction in the percentage of non-relevant positive results for carcinogenicity prediction can be achieved by careful selection of cells used without decreasing the sensitivity of the assays. Therefore, the WG suggested using p53- competent - preferably human - cells in in vitro micronucleus or chromosomal aberration tests. The use of the hepatoma cell line HepaRG for genotoxicity testing was considered promising since these cells possess better phase I and II metabolizing potential compared to cell lines commonly used in this area and may overcome the need for the addition of S9. For dermally applied compounds, the WG agreed that in vitro reconstructed skin models, once validated, will be useful to follow up on positive results from standard in vitro assays as they resemble the properties of human skin (barrier function, metabolism). While the reconstructed skin micronucleus assay has been shown to be further advanced, there was also consensus that the Comet assay should be further evaluated due to its independence from cell proliferation and coverage of a wider spectrum of DNA damage.
99 citations
••
TL;DR: The presented return loss and radiation pattern results demonstrate that antenna properties have negligible variations when bent at different angles (a possible condition when placed on body) or placed in adverse conditions (under extreme heat and humidity).
Abstract: This letter presents the design of an ultrawideband (UWB) band-notched wearable antenna and its validation using simulation and measurement results. The antenna can be used for ultrawideband applications, while rejecting the higher band assigned to wireless local area network (WLAN 5.25-GHz band). The presented return loss and radiation pattern results demonstrate that antenna properties have negligible variations when bent at different angles (a possible condition when placed on body) or placed in adverse conditions (under extreme heat and humidity). Moreover, reliable performance of antenna for on-body scenario makes the designed antenna a promising candidate for wearable applications.
99 citations
••
TL;DR: Doxorubicin-induced mitophagy and mitochondrial damage in cardiomyocytes are mediated, at least in part, by dysregulation of the PINK1/parkin pathway.
99 citations
••
TL;DR: The greatest advantage for the silver graft is its ease of use but the risk of reinfection remains significant, and in-situ reconstruction with thesilver graft confirms similarity with other modalities.
98 citations
Authors
Showing all 3892 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jie Zhang | 178 | 4857 | 221720 |
Oscar H. Franco | 111 | 822 | 66649 |
Timothy J. Foster | 98 | 420 | 32338 |
Christopher P. Denton | 95 | 675 | 42040 |
Ian Kimber | 91 | 620 | 28629 |
Michael J. Gidley | 86 | 420 | 24313 |
David Carling | 86 | 186 | 45066 |
Anthony Turner | 79 | 489 | 24734 |
Rhys E. Green | 78 | 285 | 30428 |
Vijay Kumar Thakur | 74 | 375 | 17719 |
Dave J. Adams | 73 | 283 | 19526 |
Naresh Magan | 72 | 400 | 17511 |
Aedin Cassidy | 70 | 218 | 17788 |
David A. Basketter | 70 | 325 | 16639 |
Richard C. Strange | 67 | 249 | 17805 |